“DOSE OF REALITY” Big Pharma’s True Track Record Is A Hard Pill To Swallow: Part III

In advance of the U.S. Senate Committee on Finance hearing on February 26, 2019, the Campaign for Sustainable Rx Pricing (CSRxP) is releasing a blog series on what lawmakers can expect to hear from the seven pharma executives who will attend — and why their rhetoric rings hollow when measured against their companies’ track record.

We’re taking a look at the unkept pledges, proclamations and promises made by Big Pharma that lawmakers should be prepared to confront with a “dose of reality.”

Yesterday, we examined the record of AstraZeneca compared to the pledges of CEO Pascal Soriot.

Today, we will look at the rhetoric of Bristol-Myers Squibb CEO Giovanni Caforio compared to his company’s track record.

 

BRISTOL MYERS SQUIBB CEO GIOVANNI CAFORIO:

Giovanni’s Guarantees:

 

HARD MEDICINE:

 

 

 

 

 

Stay tuned for our next blog tomorrow comparing another pharma CEO’s rhetoric to the reality.

CLICK HERE to read Big Pharma’s True Track Record Is A Hard Pill To Swallow: Part I.

CLICK HERE to read Big Pharma’s True Track Record Is A Hard Pill To Swallow: Part II.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.